98%
921
2 minutes
20
Liver ischemia and reperfusion (I/R) injury is characterized by oxidative stress that is accompanied by alterations of the endogenous defensive system. Emerging evidence suggests a protective role for autophagy induced by multiple stressors including reactive oxygen species. Meanwhile, heme oxygenase-1 (HO-1) has long been implicated in cytoprotection against oxidative stress in vitro and in vivo. Therefore, we investigated the impact of autophagy in the pathogenesis of liver I/R and its molecular mechanisms, particularly its linkage to HO-1. By using transmission electron microscopic analysis and biochemical autophagic flux assays with microtubule-associated protein 1 light chain 3-II, and beclin-1, representative autophagy markers, and p62, a selective substrate for autophagy, we found that reperfusion reduced autophagy both in the rat liver and in primary cultured hepatocytes. When autophagy was further inhibited with chloroquine or wortmannin, I/R-induced hepatocellular injury was aggravated. While livers that underwent I/R showed increased levels of mammalian target of rapamaycin and calpain 1 and 2, inhibition of calpain 1 and 2 induced an autophagic response in hepatocytes subjected to hypoxia/reoxygenation. HO-1 increased autophagy, and HO-1 reduced I/R-induced calcium overload in hepatocytes and prevented calpain 2 activation both in vivo and in vitro. Taken together, these findings suggest that the impaired autophagy during liver I/R, which is mediated by calcium overload and calpain activation, contributes to hepatocellular damage and the HO-1 system protects the liver from I/R injury through enhancing autophagy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.freeradbiomed.2013.12.014 | DOI Listing |
Liver Int
September 2025
Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Provincial Clinical Research Center for Natural Polymer Biological Liver, National Quality Control Center for Donated Organ Procurement, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University
Background And Aims: Hepatic ischaemia-reperfusion injury (IRI), a common complication after hepatectomy and liver transplantation (LT), is a local sterile inflammatory response driven by innate immunity. Myocyte enhancer factor-2D (MEF2D) plays an important role in immune inflammatory response by transcriptionally activating or inhibiting gene expression, which is tightly associated with the pathogenic progression of hepatic disorders. However, the role of MEF2D in hepatic IRI is still unclear.
View Article and Find Full Text PDFMol Biol Rep
August 2025
Department of Clinical Biochemistry and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, I.R. of Iran.
Background: Liver fibrosis, characterized by progressive scarring leading to cirrhosis, represents a major global health burden. Hepatocyte apoptosis drives fibrosis development, yet the molecular mechanisms remain unclear. This study investigates the role of the IGFBP-3/TMEM219 pathway in apoptosis-mediated liver fibrosis progression.
View Article and Find Full Text PDFDig Liver Dis
August 2025
Division of Gastroenterology and Digestive Endoscopy, Fondazione I.R.C.C.S. " Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.
Liver Int
September 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Celiac disease (CeD) has been linked to both autoimmunity and chronic liver disease, but most data on the link to primary biliary cholangitis (PBC) originate from small studies and have yielded conflicting results. A systematic search was performed in the databases of Medline, Embase, Cochrane and Web of Science Core Collection for studies published between 1990 and 2024, using search terms related to CeD, gluten and PBC. The search identified 2016 publications, of which 94 were read in full text.
View Article and Find Full Text PDFJ Hepatol
August 2025
Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
Background & Aims: Patients with advanced hepatocellular carcinoma (HCC) generally experience poor outcomes despite current therapies; alternative treatments are needed. ADP-A2AFP is an investigational autologous T-cell therapy with an affinity-enhanced T-cell receptor (TCR) targeting alpha-fetoprotein (AFP).
Methods: We describe a phase I, open-label, first-in-human clinical trial of ADP-A2AFP (NCT03132792) in human leukocyte antigen-eligible participants with AFP-expressing HCC (or other tumor) not amenable to transplant/resection that progressed on, were intolerant to, or refused prior systemic therapy.